"My Voice"

Order a paperback or Kindle Edition or e-book of "My Voice: A Physician's Personal Experience with Throat Cancer," the complete 282 page story of Dr. Brook's diagnosis, treatment, and recovery from throat cancer.

Order a paperback or Kindle Edition or e-book of "The Laryngectomee Guide," the 170 page practical guide for laryngectomees.

Obtain and/or view a video presentation, instructive manual and a slide presentation how to ventilate laryngectomees and neck breathers (free).

To obtain suggestions for laryngectomees how to cope with COVID-19 pandemic click the Laryngectomee Newsletter link.

Sunday, February 12, 2017

Cancer Moonshot Report Blue Panel Report 2016

The latest Cancer Moonshot report from a panel of top-tier cancer experts lays out 10 recommendations to speed progress in fighting cancer.

The working groups concentrated on opportunities in seven areas that included: Clinical Trials, enhancing data sharing, cancer Immunology, implementation of science, pediatric cancer, precision prevention and early detection, and tumor evolution and progression.

The list of recommendations from the 28-member panel are:

A. Establish a network for direct patient involvement
B. Create a clinical trials network devoted exclusively to immunotherapy
C. Develop ways to overcome cancer’s resistance to therapy
D. Build a national cancer data ecosystem
E. Intensify research on the major drivers of childhood cancers
F. Minimize cancer treatment’s debilitating side effects
G. Expand use of proven cancer prevention and early detection strategies
H. Mine past patient data to predict future patient outcomes
I. Develop a 3-D cancer atlas
J. Develop new cancer technologies

Gathering information about tumor profiles and treatment outcomes in a linked network of databases would enable more precise knowledge about what works, in whom, and in which types of cancer. This network would also allow patients to “pre-register” for clinical trials, enabling them or their physicians to be contacted if their tumor’s molecular characteristics made them eligible for clinical trials that match their cancer profile. By enabling patients to enroll directly, the network would reach a broader and more diverse.